Your blood stem cells are the source of your entire immune system. As they age, your body's defenses weaken. We led HexemBio's $10.4 million seed round because the company has found a way to make old blood stem cells young again.
Rejuvenation outside the body
HexemBio uses an engineered synthetic human yolk sac, the same biological environment that produces stem cells before birth, to rejuvenate a patient's own blood stem cells outside the body. The renewed cells are then returned through a standard IV infusion. The first clinical target is blood cancer, where rebuilding a healthy immune system can be the difference between recovery and relapse.
The company emerged from stealth with our round. It was founded by CEO Gabriel Levesque Tremblay alongside a deep scientific bench in Mo Ebrahimkhani, Samira Kiani, and Samet Yildirim. We led the seed, joined by SOSV and Seraphim Space.
Why we led the round
We fund the future first, and few futures are bigger than changing how we age. The premise is simple: the decline of blood stem cells is a major driver of aging itself. Start with the cancer patients who need it most, prove the science in the clinic, and the long-term implications reach far beyond any single disease. That is precisely the kind of audacious, well-grounded bet we look for, and we are proud to lead it.
Coverage
Read coverage ↗On this page
Companies in this story
